Brief: Acumen Publishes Phase 1 Trial Design And Clinical Development Plan For Alzheimer’S Disease Antibody

Acumen Pharmaceuticals

01/11/2022 12:57

Nov 1 (Reuters) - Acumen Pharmaceuticals Inc  ABOS.O :
    * ACUMEN PUBLISHES PHASE 1 TRIAL DESIGN AND CLINICAL
DEVELOPMENT
PLAN FOR ACU193, AN ANTI-AMYLOID BETA OLIGOMER ANTIBODY FOR
ALZHEIMER’S DISEASE
    * ACUMEN PUBLISHES PHASE 1 TRIAL DESIGN AND CLINICAL
DEVELOPMENT
PLAN FOR ACU193, AN ANTI-AMYLOID BETA OLIGOMER ANTIBODY FOR
ALZHEIMER’S DISEASE

Source text for Eikon:  ID:nGNX8xbysR 
Further company coverage:  ABOS.O 
 ((Reuters.Briefs@thomsonreuters.com;))